KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells

Background/Aim: We previously established a novel type of epidermal growth factor receptor variant III (EGFRvIII)-specific chimeric antigen receptor (CAR)-expressing natural killer (NK) cell line, designated EvCAR-KHYG-1, which inhibited the growth of glioblastoma (GBM) cells in vitro via apoptosis....

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-06, Vol.40 (6), p.3231-3237
Main Authors: Nakazawa, Tsutomu, Murakami, Toshiharu, Natsume, Atsushi, Nishimura, Fumihiko, Morimoto, Takayuki, Matsuda, Ryosuke, Nakamura, Mitsutoshi, Yamada, Shuichi, Nakagawa, Ichiro, Park, Young-Soo, Motoyama, Yasushi, Tsujimura, Takahiro, Wakabayashi, Toshihiko, Nakase, Hiroyuki
Format: Article
Language:English
Subjects:
Anticancer properties
Antigens
Apoptosis
Biotechnology
Brain cancer
Cell-mediated immunity
Chimeric antigen receptors
Cytokines
Epidermal growth factor
Glioblastoma
Growth factors
In vivo methods and tests
Interferon
Interleukin 2
Natural killer cells
Occupancy
Receptors
Tumor necrosis factor-α
Tumors
Xenografts
Xenotransplantation
γ-Interferon
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: We previously established a novel type of epidermal growth factor receptor variant III (EGFRvIII)-specific chimeric antigen receptor (CAR)-expressing natural killer (NK) cell line, designated EvCAR-KHYG-1, which inhibited the growth of glioblastoma (GBM) cells in vitro via apoptosis. Materials and Methods: We investigated the cytokine-producing effect of EvCAR-KHYG-1 cells on GBM-like cell lines and their antitumour effect using in vivo xenograft assays. Results: EvCAR-KHYG-1 cells produced interleukin-2, interferon-γ, and tumour necrosis factor-α on EGFRvIII-expressing U87MG cells. In vivo xenograft assays showed that EvCAR-KHYG-1 cells did not reduce the volume of subcutaneous tumours derived from EGFRvIII-expressing U87MG cells but did reduce tumour cell occupancy. Conclusion: EvCAR-KHYG-1 cells led to expression of cellular immunity-related cytokines on EGFRvIII-expressing U87MG in vitro but did not inhibit tumour progression due to the induction of a pseudo progression-like pathological feature. Future studies investigating the effect of different conditions in vivo are required to study the inhibition of tumour progression in GBM.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14304